The CBG gap-map what has been tested, and what has not
Grades as of 9 August 2026 · check cbgatlas.com/card/gap-map
Across 10 tracked conditions, CBG has 0 with established or demonstrated human efficacy, 1 with any human data at all, and 1 with no primary evidence. The rest are preclinical or mechanistic only. This is the honest state of the evidence.
- Conditions tracked
- 10
- With any human data
- 1
- At Established or Demonstrated
- 0
The 10 tracked conditions, with their grades
| Condition | Human | Animal | In vitro | Biochemistry | Review |
|---|---|---|---|---|---|
| Anxiety & stressgrade: Low | 1 | 0, 2 against | 0 | 0 | 0 |
next rung: Demonstrated one larger, controlled, non-acute human trial; or two independent human observational studies | |||||
| Antibacterial (MRSA)grade: Lowpreclinical only | 0 | 1 | 1 | 0 | 0 |
next rung: Emerging one animal (preclinical) effect study from a research group not already counted here; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Appetite stimulationgrade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 |
next rung: Emerging one animal (preclinical) effect study from a research group not already counted here; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Colorectal cancer (preclinical)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 |
next rung: Emerging one animal (preclinical) effect study from a research group not already counted here; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Inflammatory bowel disease (colitis)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 |
next rung: Emerging one animal (preclinical) effect study from a research group not already counted here; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Neuroinflammationgrade: Lowpreclinical only | 0 | 0 | 1 | 0 | 0 |
next rung: Emerging two animal (preclinical) effect studies from independent research groups, agreeing in direction; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Neuroprotection (Huntington's disease)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 |
next rung: Emerging one animal (preclinical) effect study from a research group not already counted here; or one human trial of any size — including a small, short (acute / single-dose) one | |||||
| Blood pressure / cardiovasculargrade: Hypothesized | 0 | 0 | 1 | 0 | 0 |
next rung: Low one in-vitro / laboratory effect study; or one animal (preclinical) effect study from a research group not already counted here | |||||
| Skinevidence state: Mechanism only | not linked in the data | not linked in the data | not linked in the data | not linked in the data | not linked in the data |
next rung: Low one in-vitro / laboratory effect study; or one animal (preclinical) effect study from a research group not already counted here | |||||
| Intraocular pressure (glaucoma)evidence state: No primary evidence | 0 | 0 | 0 | 0 | 0 |
next rung: Low one in-vitro / laboratory effect study; or one animal (preclinical) effect study from a research group not already counted here | |||||
Counts are registry studies linked to each condition’s claim, by study type; 9 of 10 rows carry a linkage, and a row shown “—” has none in our data. A grade sits at or below what its studies allow, never above. The rungs are defined on How we grade; the full map is the gap-map.
Cardiovascular note grade: grade: Hypothesized
CBG may influence blood pressure via α2-adrenoceptor activity; the direction and magnitude of any human effect are uncharacterized. Mechanistic plausibility only: the receptor activity has been measured in the laboratory, and no study has measured a blood-pressure effect of CBG in a person. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
Informational only, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease, and none of these rows is evidence of benefit. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.